Biosimilars – Forecast – Endocrinology
In 2023, sales of insulins at the ex-manufacturer price level exceeded $19 billion in the major pharmaceutical markets under study (United States, EU5, and Japan); G7 sales for Prolia exceeded $3 billion. Throughout our 2023-2033 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi as well as Amgen / Daiichi Sankyo’s Prolia / Pralia will face increasing competition from biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecast for key reference brand insulins and antiresorptive analogues and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Endocrinology
Related Market Assessment Reports
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
